NAMS Menopause Certification Exam
(MSCP) 2026/2027: 300 Practice Questions
with Verified Answers & Rationales
Menopause Society Certified Practitioner
Test Bank
Domain 1: Reproductive Physiology & STRAW+10 Staging (Questions 1–40)
1. A 51-year-old woman presents with moderate-to-severe hot flashes and
night sweats. She has an intact uterus and no significant past medical history.
Which is the most appropriate initial hormone therapy regimen?
A) Conjugated equine estrogens 0.45 mg daily alone
B) Continuous combined oral estradiol 1 mg / drospirenone 0.5 mg daily
C) Transdermal estradiol 0.05 mg patch weekly alone
D) Oral micronized progesterone 100 mg daily alone
Answer B: Continuous combined oral estradiol 1 mg / drospirenone 0.5 mg
daily
Rationale: In women with an intact uterus, systemic estrogen must be paired with
a progestogen to protect against endometrial hyperplasia. Continuous combined
regimens provide both endometrial protection and effective vasomotor symptom
relief .
,2. According to the Menopause Society guidelines, what is the primary
physiological mechanism driving the “late menopausal transition” stage
(STRAW+10 Stage -1)?
A) Sustained permanent elevation of progesterone
B) Skipped cycles or amenorrhea lasting 60 days or longer
C) Complete depletion of primordial follicles
D) Decline of FSH to prepubertal levels
Answer B: Skipped cycles or amenorrhea lasting 60 days or longer
Rationale: The late menopausal transition (Stage -1) is characterized by skipped
cycles or amenorrhea lasting ≥60 days. FSH levels fluctuate but are generally
elevated; complete follicle depletion defines postmenopause .
3. A 47-year-old reports sudden change in menstrual bleeding, with cycles
shortening to 21 days and heavy, prolonged bleeding. What is the most
appropriate next step?
A) Reassure her this is normal perimenopause
B) Perform endometrial biopsy
C) Order pelvic ultrasound and serum TSH
D) Initiate high-dose oral contraceptives
Answer C: Order pelvic ultrasound and serum TSH
Rationale: Abnormal uterine bleeding in perimenopause requires evaluation
before starting hormonal treatment. Initial workup includes structural evaluation
(ultrasound) and systemic causes (TSH) .
,4. Which biomarker is the most reliable and earliest indicator of declining
ovarian reserve during the early menopausal transition?
A) Anti-Müllerian Hormone (AMH)
B) Luteinizing Hormone (LH)
C) Estrone (E1)
D) Inhibin A
Answer A: Anti-Müllerian Hormone (AMH)
Rationale: AMH declines before FSH elevation, making it one of the earliest and
most sensitive markers of declining oocyte pool, though clinical staging is based
on menstrual cycles .
5. A 53-year-old requests non-hormonal treatment for severe VMS due to ER-
positive breast cancer. Which non-hormonal prescription therapy is FDA-
approved specifically for moderate-to-severe VMS?
A) Gabapentin
B) Clonidine
C) Paroxetine mesylate
D) Venlafaxine
Answer C: Paroxetine mesylate
Rationale: Paroxetine mesylate (Brisdelle) is the only non-hormonal prescription
FDA-approved specifically for moderate-to-severe vasomotor symptoms. Other
agents are used off-label .
, 6. Menopause is defined as:
A) The onset of perimenopausal symptoms
B) 12 consecutive months of amenorrhea without other pathologic cause
C) The cessation of ovarian hormone production
D) The end of fertility
Answer B: 12 consecutive months of amenorrhea without other pathologic
cause
Rationale: Menopause is confirmed retrospectively after 12 consecutive months
without menstruation. It is a single day (final menstrual period), not a phase .
7. Which ethnic group tends to have a slightly later mean age of menopause?
A) White
B) African American
C) Hispanic
D) Asian
Answer C: Hispanic
Rationale: Hispanic women have later menopause (~52 years) compared to White
(~51 years). African American women have earlier menopause by ~6-12 months .
8. Smoking is associated with menopause that occurs:
A) 1–2 years earlier
B) 5–7 years earlier
(MSCP) 2026/2027: 300 Practice Questions
with Verified Answers & Rationales
Menopause Society Certified Practitioner
Test Bank
Domain 1: Reproductive Physiology & STRAW+10 Staging (Questions 1–40)
1. A 51-year-old woman presents with moderate-to-severe hot flashes and
night sweats. She has an intact uterus and no significant past medical history.
Which is the most appropriate initial hormone therapy regimen?
A) Conjugated equine estrogens 0.45 mg daily alone
B) Continuous combined oral estradiol 1 mg / drospirenone 0.5 mg daily
C) Transdermal estradiol 0.05 mg patch weekly alone
D) Oral micronized progesterone 100 mg daily alone
Answer B: Continuous combined oral estradiol 1 mg / drospirenone 0.5 mg
daily
Rationale: In women with an intact uterus, systemic estrogen must be paired with
a progestogen to protect against endometrial hyperplasia. Continuous combined
regimens provide both endometrial protection and effective vasomotor symptom
relief .
,2. According to the Menopause Society guidelines, what is the primary
physiological mechanism driving the “late menopausal transition” stage
(STRAW+10 Stage -1)?
A) Sustained permanent elevation of progesterone
B) Skipped cycles or amenorrhea lasting 60 days or longer
C) Complete depletion of primordial follicles
D) Decline of FSH to prepubertal levels
Answer B: Skipped cycles or amenorrhea lasting 60 days or longer
Rationale: The late menopausal transition (Stage -1) is characterized by skipped
cycles or amenorrhea lasting ≥60 days. FSH levels fluctuate but are generally
elevated; complete follicle depletion defines postmenopause .
3. A 47-year-old reports sudden change in menstrual bleeding, with cycles
shortening to 21 days and heavy, prolonged bleeding. What is the most
appropriate next step?
A) Reassure her this is normal perimenopause
B) Perform endometrial biopsy
C) Order pelvic ultrasound and serum TSH
D) Initiate high-dose oral contraceptives
Answer C: Order pelvic ultrasound and serum TSH
Rationale: Abnormal uterine bleeding in perimenopause requires evaluation
before starting hormonal treatment. Initial workup includes structural evaluation
(ultrasound) and systemic causes (TSH) .
,4. Which biomarker is the most reliable and earliest indicator of declining
ovarian reserve during the early menopausal transition?
A) Anti-Müllerian Hormone (AMH)
B) Luteinizing Hormone (LH)
C) Estrone (E1)
D) Inhibin A
Answer A: Anti-Müllerian Hormone (AMH)
Rationale: AMH declines before FSH elevation, making it one of the earliest and
most sensitive markers of declining oocyte pool, though clinical staging is based
on menstrual cycles .
5. A 53-year-old requests non-hormonal treatment for severe VMS due to ER-
positive breast cancer. Which non-hormonal prescription therapy is FDA-
approved specifically for moderate-to-severe VMS?
A) Gabapentin
B) Clonidine
C) Paroxetine mesylate
D) Venlafaxine
Answer C: Paroxetine mesylate
Rationale: Paroxetine mesylate (Brisdelle) is the only non-hormonal prescription
FDA-approved specifically for moderate-to-severe vasomotor symptoms. Other
agents are used off-label .
, 6. Menopause is defined as:
A) The onset of perimenopausal symptoms
B) 12 consecutive months of amenorrhea without other pathologic cause
C) The cessation of ovarian hormone production
D) The end of fertility
Answer B: 12 consecutive months of amenorrhea without other pathologic
cause
Rationale: Menopause is confirmed retrospectively after 12 consecutive months
without menstruation. It is a single day (final menstrual period), not a phase .
7. Which ethnic group tends to have a slightly later mean age of menopause?
A) White
B) African American
C) Hispanic
D) Asian
Answer C: Hispanic
Rationale: Hispanic women have later menopause (~52 years) compared to White
(~51 years). African American women have earlier menopause by ~6-12 months .
8. Smoking is associated with menopause that occurs:
A) 1–2 years earlier
B) 5–7 years earlier
